Related Experiment Video
Updated: Jun 6, 2026
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Have we made progress in the management of chronic graft-vs-host disease?
1University of Washington, Seattle, 98109, United States. sjlee@fhcrc.org
Insights
Progress in managing chronic graft-vs-host disease (GVHD) remains limited, despite promising new treatments. Consensus on GVHD definitions and trials aims to standardize research for future clinical advancements.
Area of Science:
- Hematology
- Immunology
- Transplant Medicine
Background:
- Chronic graft-vs-host disease (GVHD) is a significant complication following allogeneic hematopoietic cell transplant.
- High rates of morbidity and mortality are associated with chronic GVHD, impacting patient outcomes.
Purpose of the Study:
- To define meaningful progress in the management of chronic GVHD.
- To assess current advancements in chronic GVHD treatment and prevention strategies.
Main Methods:
- Review of current literature and clinical trial data.
- Analysis of proposed indicators for improved chronic GVHD management.
- Identification of consensus points within the research community.
Main Results:
- No substantial progress has been demonstrated in reducing chronic GVHD incidence or severity, or improving survival rates.
- Promising new preventive strategies and treatments for chronic GVHD are emerging.
- Consensus has been reached on key issues regarding chronic GVHD definitions, management, and clinical trial conduct.
Conclusions:
- Standardized definitions and data collection are crucial for future research.
- Consensus documents will facilitate direct comparisons and drive real clinical progress in chronic GVHD.
- Continued research and development of novel therapies are necessary to improve outcomes for patients with chronic GVHD.
Abstract:
Chronic graft-vs-host disease (GVHD) is a common long-term complication of allogeneic hematopoietic cell transplant that is associated with very high morbidity and mortality. In order to understand whether we have made progress in the management of chronic GVHD, it is helpful to first propose a definition of meaningful "progress". The following can be considered to be indicators of improved management of chronic GVHD: a decrease in the incidence or severity of chronic GVHD, better efficacy or decreased toxicity of therapies, better quality of life despite chronic GVHD, and improved overall and disease-free survival rates. However, to date, real progress has not been made in these areas, though there are promising new preventive strategies and treatments. Furthermore, a consensus has been reached in the research community about many different issues surrounding chronic GVHD definitions, management, and the conduct of clinical trials. These consensus documents will help to standardize efforts and data collection so that true comparisons can be made in the future and real clinical progress achieved.
More Related Videos
09:50Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice
Published on: February 11, 2019
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
Related Concept Videos
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:40Cell-mediated Immune Responses
01:16Kidney Transplant III: Nursing Management
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation